Mastodon

Tamotsu (Capsules) Instructions for Use

Marketing Authorization Holder

Fyodorov Dmitry Vyacheslavovich, Sole Proprietor (Russia)

Manufactured By

B&S Corporation, Co. Ltd. (Japan)

Contact Information

B&S Corporation Co. Ltd. (Japan)

Dosage Form

Bottle OTC Icon Tamotsu Capsules: 60 pcs.

Dosage Form, Packaging, and Product Composition

Capsules with a mass of 230 mg.

Composition: ubiquinone (coenzyme Q10), scallop extract, fatty acids (myristic, oleic, palmitic, stearic, and their mixtures), calcium salts (anticaking agent (E470)), capsule shell (hydroxypropyl methylcellulose (E464)).

10 pcs. – blisters (6) – cardboard packs.

Therapeutic Category

Dietary supplement – source of coenzyme Q10

Properties

This dietary supplement is intended for the prevention of premature brain aging. High therapeutic efficacy is ensured by the action of the components included in the product’s composition.

Tamotsu is a natural source of plasmalogens and coenzyme Q10.

Plasmalogens (Plasmalogen) are a structural component of cells in energy-intensive organs (brain, heart, lungs, eyes, and immune system). They possess antioxidant properties. The level of plasmalogens in various systems and organs of our body can reach up to 70%. With age, the content of plasmalogens decreases, as a result of which a person’s energy-intensive organs “wear out” and their cells need “repair”. A significant decrease in the content of ethanolamine plasmalogen (pl-PE) has been established in the brain tissues of patients suffering from Alzheimer’s disease. Plasmalogens in Tamotsu are extracted from deep-sea mollusks in Japan and are 100% absorbed by the human body.

Coenzyme Q10 is a substance used in the process of cellular respiration. Its amount in the body decreases with aging. When the amount of coenzyme Q10 in the body increases, not only is the aging process slowed down, but the risk of heart attacks is also reduced due to improved cellular respiration in the heart muscle, the antiviral action of the coenzyme (reducing the likelihood of inflammatory changes in the heart muscle), as well as its antiarrhythmic properties. Furthermore, coenzyme Q10 strengthens the immune system, possesses antioxidant properties, and reduces blood pressure.

Tamotsu helps improve the condition in cases of memory problems, forgetfulness, age-related memory deterioration; decreased concentration, absent-mindedness; Alzheimer’s disease, dementia; increased psycho-emotional stress; consequences of asthenic syndrome manifested by functional disorders; engaging in heavy physical labor and sports.

Furthermore, Tamotsu is recommended for use to accelerate recovery in the postoperative period and after past illnesses, as well as to maintain the function of the cardiovascular system (including in ischemia, myocardial dystrophy, arrhythmia, atherosclerosis, arterial hypertension).

Scope of Application

Of the Tamotsu product

As a dietary supplement – a source of coenzyme Q10, for the following diseases and conditions

  • Cognitive fatigue (information exhaustion, chronic fatigue, psycho-emotional overload, attention deficit, memory loss, sleep disorders, mood instability);
  • Vascular diseases (cerebral infarction in “strategic zones”, chronic cerebral ischemia, multi-infarct state, atherosclerosis);
  • Neurodegenerative diseases (Alzheimer’s disease, dementia with Lewy bodies, Parkinson’s disease);
  • Metabolic disorders (diabetes mellitus, liver, kidney, thyroid diseases);
  • Cardiovascular diseases (various forms of coronary artery disease, arterial hypertension, myocardial dystrophy, cardiac rhythm and conduction disorders);
  • Recovery after surgeries and injuries.

ICD codes

ICD-10 code Indication
E07.9 Unspecified thyroid disorder
E14 Unspecified diabetes mellitus
E63.8 Other specified types of nutritional deficiency
F07 Personality and behavioral disorders due to disease, damage or dysfunction of the brain
F51.2 Nonorganic disorders of the sleep-wake schedule
G20 Parkinson's disease
G30 Alzheimer's disease
G31.8 Other specified degenerative diseases of the nervous system
I10 Essential [primary] hypertension
I25.9 Chronic ischemic heart disease, unspecified
I49.9 Cardiac arrhythmia, unspecified
I51.5 Myocardial degeneration
I63 Cerebral infarction
I67.2 Cerebral atherosclerosis
I67.8 Other specified cerebrovascular diseases (including cerebral ischemia (chronic))
K76.9 Liver disease, unspecified
N28.9 Disorder of kidney and ureter, unspecified
R45.8 Other symptoms and signs involving emotional state (suicidal thoughts (tendencies))
Z54 Convalescence
Z73.0 Burn-out
Z73.3 Stress, not elsewhere classified (physical and mental strain)
ICD-11 code Indication
5A0Z Thyroid diseases or thyroid dysfunctions, unspecified
5A14 Diabetes mellitus, type unspecified
5B7Z Malnutrition, unspecified
5C53.24 Leigh syndrome
6D80.Z Dementia due to Alzheimer's disease, onset unknown or unspecified
6E68 Secondary emotionally labile personality disorder
6E6Z Unspecified secondary mental or behavioral syndromes
7B2Z Sleep-wake cycle disorders, unspecified
8A00.0Z Parkinson's disease, unspecified
8A0Y Other specified movement disorders
8A20 Alzheimer's disease
8A21.0 Posterior cortical atrophy
8A2Z Neurocognitive disorders as the primary clinical feature, unspecified
8B11 Cerebral ischemic stroke
8B1Z Cerebral ischemia, unspecified
8B22 Certain specified cerebrovascular diseases
8B44.0Z Hereditary spastic paraplegia, unspecified
8D40.0 Encephalopathy due to nutritional deficiency
8E4A.0 Paraneoplastic or autoimmune disorders of the central nervous system, including brain and spinal cord
BA00.Z Essential hypertension, unspecified
BA5Z Chronic ischemic heart disease, unspecified
BC4Z Diseases of myocardium or cardiac chambers, unspecified
BC64 Sudden arrhythmic death syndrome
BD55 Asymptomatic stenosis of intracranial or extracranial artery
BE2Y Other specified diseases of the circulatory system
DB98.8 Passive congestion of liver
DB99 Other specified diseases of liver
DB9Z Liver diseases, unspecified
GB90.Y Other specified diseases of kidney or ureter
LD90.1 Early-onset parkinsonism-mental retardation
MB22.0 Abulia
MC4Y Other specified symptoms or signs involving the ear or mastoid process
ME66.Y Other specified skin changes
MF3Y Other specified symptoms, signs, or clinical findings related to the female genital system
MG23 Fear of death
MG24.00 Fear of malignant neoplasm of digestive organs
MG24.01 Fear of malignant neoplasm of breast
MG24.02 Fear of malignant neoplasm of male genital organs
MG24.0Y Other specified fear of cancer
MG24.0Z Fear of cancer, unspecified
MG24.1 Fear of human immunodeficiency virus
MG24.2 Fear of hematological disease
MG24.3 Fear of digestive system disease
MG24.4 Fear of eye diseases
MG24.5 Fear of heart disease
MG24.6 Fear of hypertensive disease
MG24.7 Fear of cardiovascular disease
MG24.8 Fear of musculoskeletal disease
MG24.9 Fear of neurological disease
MG24.A Fear of respiratory disease
MG24.B Fear of diseases of the endocrine system, nutritional disorders, or metabolic disorders
MG24.C Fear of diseases of the urinary system
MG24.D Fear of developing pregnancy complications
MG24.E Fear of a sexually transmitted disease in women
MG24.F Fear of a disease of the female genital organs or breast
MG24.G Fear of a sexually transmitted disease in men
MG24.H Fear of diseases of the male genital organs
MG24.Y Other specified fear of disease
MG24.Z Fear of disease, unspecified
QB7Z Convalescence, unspecified
QD85 Burn-out
QE01 Stress, not elsewhere classified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Take orally with meals.

Adults – 1 capsule 2 times/day.

Duration of administration – 1 month.

Contraindications

  • Individual intolerance to the product components;
  • Pregnancy;
  • Breastfeeding period.

Use during pregnancy and lactation

The use of the product is contraindicated during pregnancy and lactation.

Special instructions

This is a dietary supplement, not a medicinal product.

Consultation with a doctor is recommended before use.

Dispensing Status

Points of sale are determined by the national legislation of the member states of the Eurasian Economic Union.

Storage Conditions

The product should be stored in a cool, dry place, protected from light and out of reach of children, at a temperature not exceeding 25°C (77°F).

Shelf Life

Shelf life – 2 years.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS